

## ANNOVIS BIO, INC.

## **FORM 8-A12B**

(Securities Registration (section 12(b)))

### Filed 01/28/20

Address 1055 WESTLAKES DRIVE, SUITE 300

BERWYN, PA, 19312

Telephone 610-727-3913

CIK 0001477845

Symbol ANVS

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Medical Research

Sector Healthcare

Fiscal Year 12/31

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### FORM 8-A

# FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

### ANNOVIS BIO, INC.

(Exact name of registrant as specified in its charter)

Delaware	26-2540421
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification Number)
1055 Westlakes Drive, Suite 300 Berwyn, PA 19312	19312
(Address of principal executive offices)	(Zip Code)
Securities to be registered pursuant	to Section 12(b) of the Act:
Title of each class	Name of each exchange on which
to be so registered	each class is to be registered
Common Stock, par value \$0.0001 per share	NYSE American
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.	
If this form relates to the registration of a class of securities pursuant to Section $12(g)$ of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. $\Box$	
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.   Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-232529	

#### Item 1. Description of Registrant's Securities to be Registered.

Annovis Bio, Inc., a Delaware corporation (the "Registrant"), hereby incorporates by reference the description of its common stock, par value \$0.0001 per share, to be registered hereunder contained under the heading "Description of Our Capital Stock" in the Registrant's Registration Statement on Form S-1 (File No. 333-232529), as initially filed publicly with the Securities and Exchange Commission (the "Commission") on July 3, 2019, as amended (the "Registration Statement"), and in the prospectus included in the Registration Statement to be filed separately by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which prospectus shall be deemed to be incorporated by reference herein.

#### Item 2. Exhibits.

In accordance with the "Instructions as to Exhibits" with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on NYSE American and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

### SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Date: January 28, 2020 ANNOVIS BIO, INC.

By: /s/ Maria Maccecchini

Name: Maria Maccecchini

Title: President and Chief Executive Officer